Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery to improve treatments for patients, today announced that ...
Therefore, we would like to discuss different vector delivery systems from the perspective of designing a successful cardiovascular gene therapy protocol in large animal models. Comprehensive ...
In a recent study posted to the bioRxiv* preprint server, researchers describe a mucosal vector vaccine for targeting dendritic cells. Study: A synthetic delivery vector for mucosal vaccination. Image ...
Viral vectors used to deliver gene therapies undergo spontaneous changes during manufacturing which affects their structure and function. As gene therapy approaches become more common for treating ...
Investigators headed by a team at Brigham and Women’s Hospital have developed an adeno-associated virus (AAV) vector that studies show can far more efficiently cross the blood-brain barrier (BBB), in ...
South Korean scientists breached the blood-brain barrier in mice with a "drug delivery vector" that could ferry cancer treatments to hard-to-treat tumors. Report ...
AMSTERDAM & BOSTON & SEATTLE--(BUSINESS WIRE)--VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, and ...
Versant Ventures has committed $30 million to improve gene delivery. By pumping the cash into Vector BioPharma, the VC is aiming to address the limitations of existing systems such as the cap on the ...
VectorY Therapeutics and Shape Therapeutics Announce Option and License Agreement to Advance Vectorized Antibodies for Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid ~ Agreement grants ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback